Want to join the conversation?
$ALXN's Soliris (eculizumab) net product sales for 1Q16 grew to $665MM from $600MM in the previous year quarter. Net product sales grew 11% YoverY, despite continued currency headwinds as well as increased macroeconomic weakness in Latin American countries, primarily Brazil and Argentina. Soliris volume increased 18% YoverY.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)